The US Food and Drug Administration's (FDA) decision last week to allow the use of new qualified health claims relating to the consumption of omega-3 fatty acids and their blood pressure lowering benefits may lead to increased consumption of omega-3 rich seafood and health supplements, the Global Organization for EPA and DHA Omega-3s (GOED) said.

The group, representing omega-3 oil producers and ancillary businesses, said it considers the development to be a scientifically backed win for both the seafood and omega-3 supplement industries.